Hannah Valantine, Director at BridgeBio Pharma, Inc. (BBIO), sold 50,968 shares at $66.07 ($3.4M) on 2025-11-12, disclosed to the SEC on 2025-11-14.
Open-market sale of $3.4M BBIO by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $66.07 | 25,484 | $1.7M | 50.0% |
| 2 | $66.07 | 25,484 | $1.7M | 50.0% |
| Total | $66.07 avg | 50,968 | $3.4M | 100% |
| Filing → |
| CDNA | SELL | 2026-06-16 | $280K | — | Filing → |
| BBIO | SELL | 2026-03-12 | $624K | — | Filing → |
| BBIO | SELL | 2026-03-03 | $1.7M | — | Filing → |